The present invention relates to peptides capable of forming a gel and to their use in tissue engineering and bioprinting. The present invention furthermore relates to a gel comprising a peptide in accordance with the present invention, to a method of preparing such gel and to the use of such gel. In one embodiment, such gel is a hydrogel. The present invention furthermore relates to a wound dressing or wound healing agent comprising a gel according to the present invention and to a surgical implant or stent comprising a peptide scaffold formed by a gel according to the present invention. Moreover, the present invention also relates to a pharmaceutical and/or cosmetic composition, to a biomedical device or an electronic device comprising the peptide according to the present invention.

The present invention is related to the use of HMGB1 antagonists, specifically derivatives of K883 in the treatment and/or prevention and/or inhibition of neuropathy pain, and in particular diabetic neuropathy in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

The present disclosure provides compounds of Formula I for use in the treatment of medical disorders by the inhibition of human epididymal protein 4 (HE4).

##STR00001##

The present disclosure provides compounds of Formula I for use in the treatment of medical disorders by the inhibition of human epididymal protein 4 (HE4).

##STR00001##

Present invention discloses particular peptide sequences of formula (I);

(R.sup.1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R.sup.2).sub.(n)   (I) (SEQ ID NO: 1);

wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss.

Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Present invention discloses particular peptide sequences of formula (I);

(R.sup.1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R.sup.2).sub.(n)   (I) (SEQ ID NO: 1);

wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss.

Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Present invention discloses particular peptide sequences of formula (I); (R1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R2).sub.(n) (I) (SEQ ID NO: 1); wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss. Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Present invention discloses particular peptide sequences of formula (I); (R1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R2).sub.(n) (I) (SEQ ID NO: 1); wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss. Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).